Ephenidine (also known as NEDPA and EPE) is a lesser-known dissociative substance of the diarylethylamine class. Ephenidine is an NMDA receptor antagonist that is structurally related to diarylethylamines like diphenidine and methoxphenidine. Notable effects include sedation, hallucinations, anesthesia, and out-of-body states, referred to as “dissociative anesthesia”.
Ephenidine and related diarylethylamines have been studied in humans as treatments for neurotoxic injuries.
Ephenidine is a molecule of the diarylethylamine class. It contains a substituted phenethylamine skeleton with an additional phenyl ring bound to Rα. An ethyl chain is bound to the terminal amine RN of the phenethylamine. Ephenidine is structurally analogous to diphenidine and MXP, but is not a piperidine dissociative. Ephenidine shares a diphenylethylamine skeleton with diphenidine and MXP, but lacks a piperidine substitution.
Ephenidine acts as an antagonist of the NMDA receptor (Ki = 66.4 nM).
The NMDA (N-methyl-D-aspartate) receptor is one of the major receptor subtypes for glutamate, the major excitatory neurotransmitter in the central nervous system (CNS). When NMDA channels are blocked,a loss of feeling (anesthesia), difficulty moving (immobilization), and at higher doses, the compound’s equivalent of the “K-hole” results.
Stimulation – This compound produces stimulating effects at lower doses which are less intense than that of diphenidine or methoxphenidine.
Ephenidine is sold for research purposes only and is not be utilized for any other purposes.